Gabelli Radio

Daniel Barasa sits down with GabelliTV to provide the skinny on Eli Lilly's Tirzepatide weight loss drug and its recent FDA Approval. To learn more about Gabelli Funds' disciplined, research driven approach to investing, visit https://m.gabelli.com/gtv_cu or email invest@gabelli.com. Connect with Gabelli Funds: • Twitter - https://twitter.com/InvestGabelli • Instagram - https://www.instagram.com/investgabelli/ • Facebook - https://www.facebook.com/InvestGabelli • LinkedIn - https://www.linkedin.com/company/inve... http://www.Gabelli.com Invest with Us 1-800-GABELLI (800-422-3554)